Vaxart Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Steven Lo

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3yrs
Durée moyenne du mandat des membres du conseil d'administration	3.3yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Steven Lo (57 yo)

less than a year

Titularisation

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Sean Tucker	Senior VP & Chief Scientific Officer	14.8yrs	US$1.14m	0.10% € 136.5k
James Cummings	Chief Medical Officer	3.3yrs	US$1.17m	0.063% € 83.1k
Steven Lo	President	less than a year	pas de données	pas de données
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	1.9yrs	pas de données	0.036% € 46.9k
Raymond Stapleton	Chief Technology Officer	2.3yrs	pas de données	pas de données
Edward Berg	Senior VP & General Counsel	2.8yrs	pas de données	0.050% € 65.2k
Shaily Garg	Senior Vice President of Clinical Development & Project Management	4.7yrs	pas de données	pas de données
Rajesh Kapoor	Senior Vice President of Quality	3.8yrs	pas de données	pas de données

3.0yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de NB11 est considérée comme expérimentée (ancienneté moyenne 3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Steven Lo	President	less than a year	pas de données	pas de données
Robert Yedid	Independent Director	5.1yrs	US$92.26k	0.0081% € 10.7k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.3yrs	pas de données	pas de données
Elaine Heron	Independent Director	2.3yrs	US$89.08k	0.011% € 14.2k
Michael Finney	Independent Chairman of the Board	6.8yrs	US$109.57k	0.29% € 386.6k
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.3yrs	pas de données	pas de données
David Wheadon	Independent Director	3.6yrs	US$93.72k	0.0065% € 8.5k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.3yrs	pas de données	pas de données
William Watson	Independent Director	2.3yrs	US$94.76k	0.023% € 30.1k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.3yrs	pas de données	pas de données
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.3yrs	pas de données	pas de données
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.3yrs	pas de données	pas de données

3.3yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de NB11 sont considérés comme expérimentés (ancienneté moyenne 3.3 ans).

Vaxart Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

High number of new and inexperienced directors

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Recent updates

Third quarter 2024 earnings released: US$0.062 loss per share (vs US$0.11 loss in 3Q 2023)

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023)

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Now 40% undervalued after recent price drop

Now 21% undervalued after recent price drop

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023)

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Now 21% undervalued after recent price drop

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022)

Full year 2022 earnings released: US$0.84 loss per share (vs US$0.58 loss in FY 2021)

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.13 loss in 2Q 2021)

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2021)

No longer forecast to breakeven

High number of new and inexperienced directors

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

Forecast to breakeven in 2024

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2020)

Forecast to breakeven in 2023

Vaxart, Inc. Announces FDA Clearance IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

No longer forecast to breakeven

No longer forecast to breakeven

Vaxart, Inc. Announces First Subject Enrolled in Phase 1B Norovirus Dose-Ranging Trial in Elderly Adults

Vaxart, Inc. Announces First Subject Enrolled in Phase 1B Norovirus Boosting Regimen Study